If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns
Eli Lilly: Still the industry leader Novo Nordisk was first to market, but Eli Lilly 's (NYSE: LLY) GLP-1 shot proved more effective
Patients typically shoulder the cost
Both medications can slow gastric emptying, which may affect how quickly oral medications (including the contraceptive pill) are absorbed
Luboshitzky, R., Shen-Orr, Z., Nave, R., Lavi, S., & Lavie, P
